• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肺腺癌中的 hsa_circ_0079929 及其对肺腺癌进展的生物学意义。

Hsa_circ_0079929 in lung adenocarcinoma and its biological implications in lung adenocarcinoma progression.

机构信息

Department of Internal Medicine, Huzhou Jiaotong Hospital, Huzhou, 313000, China.

Department of Oncology, Yuhuan Second People's Hospital, Yuhuan, 317605, China.

出版信息

J Cardiothorac Surg. 2024 Sep 28;19(1):549. doi: 10.1186/s13019-024-03075-1.

DOI:10.1186/s13019-024-03075-1
PMID:39342367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11437964/
Abstract

BACKGROUND

This report investigated the expression, prognostic and biological implications of hsa_circ_0079929 in lung adenocarcinoma, which was based on clinical and experimental data.

METHODS

Patients with lung adenocarcinoma were screened and their clinical data and tissues (including cancerous tissues and adjacent normal tissues) were collected. The total RNA in tissues and cell lines was analyzed to obtained hsa_circ_0079929 level. The clinical significance was examined using the Chi-square test, Multi-variate Cox proportional hazards regression, and Kaplan-Meier curve. Cell malignant features were evaluated from three aspects (proliferation, migration, and invasion), detected by CCK-8 and Transwell methods.

RESULTS

Hsa_circ_0079929 raised in expression level in lung adenocarcinoma. This upregulation of hsa_circ_0079929 was correlated with adverse clinical parameters and poor outcome in terms of overall survival, resulting in an independent prognostic purpose molecular for overall survival. Overexpression of hsa_circ_0079929 could contribute to cell proliferation/migration/invasion, whereas its knockdown could inhibit these malignant features. Hsa_circ_0079929 was a molecular decoy for miR-1184 in lung adenocarcinoma cells.

CONCLUSIONS

Hsa_circ_0079929 could promote the malignant features of lung adenocarcinoma cells and may aid the follow up and therapeutic target discovery of lung adenocarcinoma.

摘要

背景

本报告基于临床和实验数据，研究了 hsa_circ_0079929 在肺腺癌中的表达、预后和生物学意义。

方法

筛选肺腺癌患者，收集其临床资料和组织（包括癌组织和癌旁正常组织）。分析组织和细胞系中的总 RNA，以获得 hsa_circ_0079929 水平。使用卡方检验、多变量 Cox 比例风险回归和 Kaplan-Meier 曲线检验临床意义。通过 CCK-8 和 Transwell 方法从增殖、迁移和侵袭三个方面评估细胞恶性特征。

结果

hsa_circ_0079929 在肺腺癌中的表达水平升高。hsa_circ_0079929 的这种上调与不良的临床参数相关，并且在总生存率方面表现出较差的预后，这使其成为总生存率的独立预后分子。hsa_circ_0079929 的过表达可促进细胞增殖/迁移/侵袭，而其敲低可抑制这些恶性特征。hsa_circ_0079929 是肺腺癌细胞中 miR-1184 的分子诱饵。

结论

hsa_circ_0079929 可促进肺腺癌细胞的恶性特征，可能有助于肺腺癌的随访和治疗靶点发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/592e89453cdc/13019_2024_3075_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/4c3bba691485/13019_2024_3075_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/34f5cc6a628d/13019_2024_3075_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/46fefeb543bb/13019_2024_3075_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/87b1722b848b/13019_2024_3075_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/592e89453cdc/13019_2024_3075_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/4c3bba691485/13019_2024_3075_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/34f5cc6a628d/13019_2024_3075_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/46fefeb543bb/13019_2024_3075_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/87b1722b848b/13019_2024_3075_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ffb/11437964/592e89453cdc/13019_2024_3075_Fig5_HTML.jpg

相似文献

1
Hsa_circ_0079929 in lung adenocarcinoma and its biological implications in lung adenocarcinoma progression.肺腺癌中的 hsa_circ_0079929 及其对肺腺癌进展的生物学意义。
J Cardiothorac Surg. 2024 Sep 28;19(1):549. doi: 10.1186/s13019-024-03075-1.
2
Circular RNA hsa_circ_0001588 promotes the malignant progression of lung adenocarcinoma by modulating miR-524-3p/NACC1 signaling.环状 RNA hsa_circ_0001588 通过调控 miR-524-3p/NACC1 信号通路促进肺腺癌的恶性进展。
Life Sci. 2020 Oct 15;259:118157. doi: 10.1016/j.lfs.2020.118157. Epub 2020 Jul 28.
3
The novel circular RNA circ-CAMK2A enhances lung adenocarcinoma metastasis by regulating the miR-615-5p/fibronectin 1 pathway.新型环状 RNA circ-CAMK2A 通过调控 miR-615-5p/纤维连接蛋白 1 通路促进肺腺癌转移。
Cell Mol Biol Lett. 2019 Dec 26;24:72. doi: 10.1186/s11658-019-0198-1. eCollection 2019.
4
[Expression of circular RNA hsa_circ_0014130 in lung adenocarcinoma cell lines and its effect on proliferation and invasion of lung adenocarcinoma cell line].[环状RNA hsa_circ_0014130在肺腺癌细胞系中的表达及其对肺腺癌细胞系增殖和侵袭的影响]
Zhonghua Bing Li Xue Za Zhi. 2019 Dec 8;48(12):934-939. doi: 10.3760/cma.j.issn.0529-5807.2019.12.004.
5
Hsa_circ_0016760 exacerbates the malignant development of non‑small cell lung cancer by sponging miR‑145‑5p/FGF5.Hsa_circ_0016760 通过海绵吸附 miR-145-5p/FGF5 来加剧非小细胞肺癌的恶性发展。
Oncol Rep. 2021 Feb;45(2):501-512. doi: 10.3892/or.2020.7899. Epub 2020 Dec 14.
6
Hsa_circ_0070661 inhibits cancer progression through miR-556-5p/TEK axis in lung adenocarcinoma.Hsa_circ_0070661通过miR-556-5p/TEK轴抑制肺腺癌的癌症进展。
Cancer Biomark. 2023;37(1):53-66. doi: 10.3233/CBM-220282.
7
Circular RNA hsa_circ_0000326 acts as a miR-338-3p sponge to facilitate lung adenocarcinoma progression.环状 RNA hsa_circ_0000326 作为 miR-338-3p 的海绵体促进肺腺癌进展。
J Exp Clin Cancer Res. 2020 Apr 5;39(1):57. doi: 10.1186/s13046-020-01556-4.
8
Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt/β-catenin pathway.环状 RNA hsa_circ_000984 的表达增强促进非小细胞肺癌细胞的增殖和转移，通过调节 Wnt/β-连环蛋白通路。
Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3366-3374. doi: 10.26355/eurrev_201904_17700.
9
Overexpression of hsa_circ_0008274 inhibited the progression of lung adenocarcinoma by regulating HMGA2 via sponging miR-578.hsa_circ_0008274 的过表达通过海绵吸附 miR-578 调控 HMGA2 抑制肺腺癌的进展。
Thorac Cancer. 2021 Aug;12(16):2258-2264. doi: 10.1111/1759-7714.14059. Epub 2021 Jul 8.
10
Aberrant expression of hsa_circ_0025036 in lung adenocarcinoma and its potential roles in regulating cell proliferation and apoptosis.hsa_circ_0025036 在肺腺癌中的异常表达及其对细胞增殖和凋亡的潜在调节作用。
Biol Chem. 2018 Nov 27;399(12):1457-1467. doi: 10.1515/hsz-2018-0303.

本文引用的文献

1
Circular RNAs and inflammation: Epigenetic regulators with diagnostic role.环状 RNA 与炎症：具有诊断作用的表观遗传调控因子。
Pathol Res Pract. 2023 Nov;251:154912. doi: 10.1016/j.prp.2023.154912. Epub 2023 Oct 26.
2
Regulation of microRNA by circular RNA.环状RNA对微小RNA的调控
Wiley Interdiscip Rev RNA. 2023 Oct 2:e1820. doi: 10.1002/wrna.1820.
3
CircRNAs and lung cancer: Insight into their roles in metastasis.环状 RNA 与肺癌：探索其在转移中的作用。
Biomed Pharmacother. 2023 Oct;166:115260. doi: 10.1016/j.biopha.2023.115260. Epub 2023 Aug 24.
4
Circular RNAs: Emerging roles and new insights in human cancers.环状 RNA：在人类癌症中的新兴作用和新见解。
Biomed Pharmacother. 2023 Sep;165:115217. doi: 10.1016/j.biopha.2023.115217. Epub 2023 Jul 26.
5
Circular RNAs-mediated angiogenesis in human cancers.环状 RNA 介导的人类癌症血管生成。
Clin Transl Oncol. 2023 Nov;25(11):3101-3121. doi: 10.1007/s12094-023-03178-6. Epub 2023 Apr 11.
6
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
7
Circular RNAs as biomarkers for lung cancer.环状RNA作为肺癌的生物标志物
Noncoding RNA Res. 2022 Nov 7;8(1):83-88. doi: 10.1016/j.ncrna.2022.11.002. eCollection 2023 Mar.
8
The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma.三级淋巴结构对肺腺癌临床病理、遗传及基因表达特征的影响。
Lung Cancer. 2022 Dec;174:125-132. doi: 10.1016/j.lungcan.2022.11.001. Epub 2022 Nov 5.
9
Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives.生物标志物靶向治疗非小细胞肺癌：现状与展望。
Cells. 2022 Oct 12;11(20):3200. doi: 10.3390/cells11203200.
10
Lung Cancer Treatment Advances in 2022.2022 年肺癌治疗进展。
Cancer Invest. 2023 Jan;41(1):12-24. doi: 10.1080/07357907.2022.2119479. Epub 2022 Dec 12.